

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

### **PROFIT WARNING**

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited management accounts of the Group for the six months ended June 30, 2022 and an assessment of the latest information currently available to the Board, despite the negative COVID impacts, the Group is expected to record a revenue of no less than RMB120 million for the six months ended June 30, 2022, representing an increase of over 40% as compared to that of the same period last year. The increase in revenue of the Group is mainly attributable to the Group's continued commercialization of VitaFlow<sup>®</sup> and VitaFlow Liberty<sup>™</sup> and the increasing number of implantations. As of June 30, 2022, there are more than 370 hospitals in China using VitaFlow<sup>®</sup> and VitaFlow Liberty<sup>™</sup>, most of which are class IIIA hospitals located at tier-one and tier-two cities.

The Group is expected to record a net loss (unaudited) of approximately RMB120 million to RMB135 million for the six months ended June 30, 2022, compared to approximately RMB70 million (unaudited) for the six months ended June 30, 2021. The expected increase in the net loss of the Group is mainly attributable to our continued investment in research and development and further commercialization efforts.

The information contained in this announcement is only based on a preliminary assessment of the consolidated management accounts and relevant revenue estimates made available to the Board as of the date of the announcement, which have not been audited or reviewed by the Company's auditors or reviewed by the audit committee of the Company, and may be subject to adjustments. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended June 30, 2022 which is expected to be published in August 2022.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Luo Qiyi**  
*Chairman*

Shanghai, PRC, August 5, 2022

*As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.*